Amjevita Shortage: What Providers and Prescribers Need to Know in 2026

As a prescriber of biologic therapies, you're likely hearing from patients who are having difficulty filling their Amjevita (Adalimumab-Atto) prescriptions. While Amjevita is not currently in a formal FDA-recognized shortage, the practical reality for many patients is that access has become more complicated. This briefing covers the current landscape, prescribing implications, and strategies you can use to help your patients maintain continuity of care.

Timeline: Amjevita's Market Entry and Evolution

Understanding the current access landscape requires context on how we got here:

• September 2016: FDA approves Amjevita (Adalimumab-Atto) as the first biosimilar to Humira.
• January 2023: Amgen launches Amjevita in the U.S. with a dual-pricing strategy — a standard WAC approximately 5% below Humira's list price ($3,288/40 mg pen) and a lower-WAC option at approximately $1,557/40 mg pen (55% discount).
• 2023-2024: Multiple competing Adalimumab biosimilars enter the U.S. market, including Hadlima, Hyrimoz, Cyltezo, Abrilada, Hulio, Simlandi, and Yuflyma.
• 2024: FDA grants interchangeability designation to several biosimilars including Amjevita for its 10 mg, 20 mg, 40 mg, and 80 mg formulations, allowing pharmacist-level substitution.
• 2025-2026: PBM formulary consolidation intensifies. Major payers select preferred biosimilars, creating a fragmented access landscape where different patients face different availability depending on their insurer.

Prescribing Implications

The competitive Adalimumab biosimilar market has created several prescribing considerations for providers:

Formulary Variability

Different insurance plans now prefer different Adalimumab biosimilars. A patient covered by one PBM may have seamless access to Amjevita, while a patient with a different plan may find that Hadlima or Hyrimoz is the preferred product. This means a one-size-fits-all prescribing approach may result in access delays for some patients.

Recommendation: Before writing a prescription for a specific Adalimumab product, verify which biosimilar is preferred on the patient's formulary. Many EHR systems now include real-time benefit check (RTBC) tools that can surface this information at the point of prescribing.

Interchangeability and Pharmacy Substitution

With Amjevita and several other biosimilars now holding FDA interchangeability designations, pharmacists can substitute these products for Humira without prescriber intervention in most states. While this increases flexibility, it also means patients may receive a different Adalimumab product than what was originally prescribed.

If you have a clinical reason to specify a particular product — for example, a patient who has had adverse reactions to a specific formulation — use dispense as written (DAW) to prevent substitution.

Non-Medical Switching Concerns

Some patients may be switched between biosimilars mid-treatment due to formulary changes rather than clinical necessity. While clinical data supports the safety of switching between Adalimumab biosimilars, frequent switches can cause patient confusion and anxiety. Consider proactively communicating with patients about biosimilar equivalence to build confidence.

Current Availability Picture

As of early 2026, the Amjevita supply chain is functioning normally from a manufacturing standpoint. Access challenges are primarily driven by:

• Specialty pharmacy distribution: Amjevita requires cold-chain storage and is primarily dispensed through specialty pharmacies, not retail locations.
• PBM formulary decisions: Different PBMs have negotiated exclusive or preferred contracts with different biosimilar manufacturers, creating a patchwork of coverage.
• Prior authorization requirements: Most plans require PA for all Adalimumab products, adding processing time and potential for denials.
• Patient confusion: Patients may not understand why their pharmacy doesn't carry the specific product prescribed, leading them to believe there's a shortage.

Cost and Access Considerations

Pricing in the Adalimumab biosimilar market varies significantly:

• Amjevita standard WAC: ~$3,288 per 40 mg pen (5% below Humira)
• Amjevita lower WAC: ~$1,557 per 40 mg pen (55% below Humira)
• Net cost after rebates: Varies by payer contract; in many cases, payer net costs are substantially below WAC for all biosimilars

For uninsured or underinsured patients, the Amgen Safety Net Foundation provides free Amjevita to qualifying patients. The Amgen SupportPlus Co-Pay Program offers $0 copay assistance for eligible commercially insured patients.

For a patient-facing resource on cost savings, refer patients to our guide to saving money on Amjevita.

Tools and Resources for Your Practice

Medfinder for Providers

Medfinder offers a provider-facing tool that helps you and your staff quickly identify pharmacies with Amjevita (or other Adalimumab biosimilars) in stock. This can be particularly useful when a patient's usual pharmacy is out of stock and you need to redirect the prescription quickly.

Amgen SupportPlus for Healthcare Professionals

Amgen's provider portal at amjevitapro.com offers prescribing resources, patient support enrollment, prior authorization support, and formulary information. The SupportPlus team can help navigate complex access issues for your patients.

Real-Time Benefit Check Tools

If your EHR supports real-time benefit check (RTBC), use it to identify the patient's preferred Adalimumab product before writing the prescription. This can prevent denials and reduce the time patients spend waiting for their medication.

Looking Ahead

The Adalimumab biosimilar market will continue to evolve through 2026 and beyond. Key trends to watch:

• Further formulary consolidation: PBMs may narrow their preferred Adalimumab product lists, potentially improving access for patients on preferred products while creating challenges for those on non-preferred ones.
• Subcutaneous Infliximab: New subcutaneous formulations of Infliximab may offer an alternative self-injectable TNF inhibitor option for some patients.
• Value-based contracts: Manufacturers and payers are exploring outcomes-based pricing arrangements that could affect preferred product designations.

Final Thoughts

While Amjevita is not in a formal shortage, the fragmented specialty pharmacy landscape and competitive formulary dynamics mean that patient access requires more active management from prescribers than in the Humira-only era. By staying informed about formulary preferences, leveraging real-time tools, and connecting patients with support programs, you can help ensure continuity of biologic therapy for your patients.

For provider-specific resources and pharmacy availability tools, visit Medfinder for Providers. For clinical guidance on helping patients navigate access challenges, see our provider's guide to helping patients find Amjevita.